Login
$SPRO
$0.93 -$0.02 (1.73%) After hours

$SPRO SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD)

12 Nov 2026 10-Q
10 Nov 2026 Form 4: Rajavelu Esther, Director

Sold 40,851 shares ($42.5K)

10 Nov 2026 Form 4: Ho William, Director

Granted 100,000 Stock Option (right to buy)

10 Nov 2026 Form 3: Ho William, Director

No securities owned

10 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

28 Oct 2026 S-8
27 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

10 Sep 2026 EFFECT
28 Aug 2026 8-K: Entry into a Material Definitive Agreement; Other Events

On August 28, 2026, Spero Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement℠ (the “Sale Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which the Company may offer ...

28 Aug 2026 S-3
12 Aug 2026 8-K: Results of Operations and Financial Condition

Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases

12 Aug 2026 10-Q
06 Aug 2026 Form 4: Zack Debra, Chief Medical Officer

Received 162,311 shares as a grant or award · Granted 324,675 Stock option (right to buy)

06 Aug 2026 Form 3: Zack Debra, Chief Medical Officer

No securities owned

14 Jul 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

On July 8, 2026, Spero Therapeutics, Inc. (the “Company”) entered into a license agreement (the “Innovent Agreement”) with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc. (collectively, “Innovent”), pursuant to w...

25 Jun 2026 Form 4: Deshpande Milind, Director

Received 10,000 shares as a grant or award · Granted 20,000 Stock Option (right to buy)

25 Jun 2026 Form 4: Tregoning Kathleen, Director

Received 10,000 shares as a grant or award · Granted 20,000 Stock Option (right to buy)

25 Jun 2026 Form 4: Smith Cynthia, Director

Received 10,000 shares as a grant or award · Granted 20,000 Stock Option (right to buy)

25 Jun 2026 Form 4: Vink Patrick V.j.j., Director

Received 10,000 shares as a grant or award · Granted 20,000 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support